Objectives: To determine if there is added value to oncology studies performed with a dedicated in-line positron emission tomography (PET)/computed tomography (CT) scanner as compared with PET read side by side with diagnostic CT (DCT).
M
any studies on various tumor types have shown that 18 F-fluoro-2-deoxy-D, glucose (FDG)-positron emission tomography (PET)/computed tomography (CT) is more sensitive and specific than 18 F-FDG PET alone in staging and restaging of various malignancies. 1 This can be attributed to the low anatomic resolution of PET and difficulty in lesion localization as well as added information from CT, which may make interpretation of findings more specific. [2] [3] [4] [5] In routine clinical practice, however, 18 F-FDG PET studies performed on nonhybrid systems are usually read side by side with contemporary anatomic imaging, most often CT. Although most agree that PET/CT scanners are convenient to use and improve patient throughput attributable to reduced acquisition time (as compared with 68 Ge-based attenuation correction), 6 controversy exists in the literature as to the need for in-line hybrid PET/CT scanners. Some argue that the use of side-byside reading of PET and diagnostic CT (SBS PET/DCT) is sufficient for accurate interpretation.
The aim of this study was to determine if there is added value to oncology studies performed with a dedicated in-line PET/CT scanner as compared with SBS PET/DCT. In addition, we sought to identify if there are specific lesion types or body regions where PET/CT would be more advantageous than SBS PET/DCT.
PATIENTS AND METHODS

Patient Selection
Forty-one consecutive patients referred for staging (n = 27) or restaging (n = 14) of malignant disease who had DCT scans available for review performed within 6 weeks of the PET/CT scan were enrolled in the study. There were 26 male and 15 female patients, with an age range of 23-82 years (mean = 53 years). The primary malignant diseases for which PET/CT was indicated included lymphoma (n = 11), lung cancer (n = 10), colorectal cancer (n = 8), esophageal cancer (n = 5), carcinoma of the cervix or endometrium (n = 4), ovarian cancer (n = 1), pancreatic cancer (n = 1), and sarcoma (n = 1). Our Institutional Review Board does not require their approval or informed consent for review of a patient's records, files, and images.
PET/CT Imaging
Patients were asked to fast for at least 4 hours before undergoing the examination. All patients had glucose levels less than 150 mg%. The patients received an intravenous injection of 370-666 MBq (10-18 mCi) 18 F-FDG. Data acquisitions were performed 60-90 minutes after injection using an integrated in-line PET/CT system (Discovery LS; General Electric Medical Systems, Milwaukee, WI). Iodinated oral contrast material was given to opacify loops of bowel on CT in all patients except those referred for staging of lung cancer.
Data acquisition was as follows. Computed tomography scanning was performed first from the head to the pelvic floor with 140 kV, 80 mA, a tube rotation time of 0.5 second, a pitch of 6, and a 5-mm section thickness, which was matched to PET section thickness. The CT part of the study was performed using a shallow breathing technique. Immediately after CT, a PET emission scan was obtained that covered the identical transverse field of view. Acquisition time was 5 minutes for each table position. Positron emission tomography image data sets were reconstructed iteratively by using CT data for attenuation correction, and coregistered images were displayed on a workstation (Xeleris; Elgems, Haifa, Israel).
Diagnostic CT Scans
All DCT scans available were performed with multidetector CT scanners. Because studies were performed at various institutions, scanning protocols varied, but all were performed using a breath-holding technique after administration of intravenous contrast. Abdominal CT scans were performed after administration of oral contrast as well. Of the 41 scans reviewed, 28 were CT scans of the chest, abdomen, and pelvis; 10 were only of the abdomen and pelvis; and 3 were of the neck, chest, abdomen, and pelvis.
Reading of Studies
A physician (O.G.) who was not involved in the imaging interpretation of the CT or PET scans was responsible for the interpretation of data sheets and performed the clinical and imaging follow-up of the imaging abnormalities identified. Only body regions with a DCT scan available were assessed. CT scans (DCT and the CT portion of PET/CT) were interpreted by 2 separate fellowship-trained radiologists (C.D.L. and U.M., respectively) in a blinded fashion, who were aware only of the patient's primary malignancy. A nuclear medicine physician experienced in PET (E.E.S.) read the PET study along with the DCT scan in consensus with 1 of the radiologists (C.D.L.) and finally read the fused PET/CT study in consensus with the other radiologist (U.M.). Attenuationcorrected and non-attenuation-corrected images (as well as the maximum intensity projection of the attenuation-corrected PET data) were available at both reading sessions. Lesions identified on DCT, the CT portion of PET/CT, SBS PET/DCT, and the reading of fused PET/CT images were scored on a 5-point scale: 0, no lesion identified; 1, benign; 2, equivocal; 3, probably malignant; and 4, definitely malignant.
Standard of Reference and Statistical Method
All lesions that were scored as definitely benign or definitely malignant on SBS PET/DCT readings and on fused PET/CT images (in absolute agreement) were considered concordant lesions. Because the purpose of this study was to assess and characterize discordant lesions between the 2 reading methods, concordant lesions were not further assessed. Two types of discordant lesions were defined: 1) fundamentally discordant lesions (ie, lesions that received a benign or equivocal score using the first reading method and a malignant score on the other) and 2) lesions that had differing degrees of confidence in reading them as benign or malignant using the 2 reading techniques. Because therapy cannot be instituted on equivocal results in clinical practice, equivocal lesions were considered benign on final analysis. Because it is unethical and often technically difficult to obtain histologic sampling from all suspected sites of imaging abnormalities in oncology patients, clinical and imaging follow-up of at least 6 months (range: 6-12 months, mean = 6 months) was used in cases in which biopsy was not clinically indicated.
The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of PET/CT and SBS PET/DCT for discordant lesions were compared using the McNemar test. P , 0.05 was considered statistically significant.
RESULTS
Of the 168 suspected abnormalities by CT or PET, 27 (16.1%) (in 19 patients) were discordant when comparing analysis of fused PET/CT images and SBS PET/DCT. Sixteen (9.5%) (in 14 patients) were fundamentally discordant, and 11(6.6%) were discordant in degree of confidence. The nature of discordant lesions was determined by histology (n = 11) or clinical and imaging follow-up (n = 16). Overall, 21 of the 27 lesions were malignant on final analysis (pathologic findings [n = 6] and imaging and clinical follow-up [n = 21]).
For all discordant lesions, the sensitivity, specificity, negative predictive value, positive predictive value, and accuracy for PET/CT were 100%, 33%, 100%, 94%, and 78%, respectively, and for SBS PET/DCT, they were 38%, 50%, 19%, 73%, and 30%, respectively (P , 0.001, x 2 value of 11.08 for sensitivity; P = not significant, x 2 value of 1.33 for specificity).
Analysis of Fundamentally Discordant Lesions
Sixteen discordant lesions were misclassified by SBS PET/DCT and correctly classified by fused PET/CT. Two main causes for misclassification on SBS PET/DCT were found: incorrect localization (n = 12) leading to false conclusions (Figs. 1, 2 ) and changes occurring in the time gap between DCT and PET/CT (n = 4). For example, a node that was of normal size when DCT was performed was clearly abnormally enlarged during the PET/CT study performed up to 6 weeks later. Findings of the 16 fundamentally discordant lesions are summarized in Table 1 . 
Analysis of Lesions With Discordant Degree of Confidence
In 11 lesions, mismatched confidence scores were recorded for fused PET/CT as compared with SBS PET/DCT (8 were malignant and 3 were benign). Reading of fused PET/CT scans resulted in a higher confidence level in the 8 malignant lesions. These lesions included subcentimetric abdominal lymph nodes (n = 5); a small peritoneal deposit in the paracolic gutter that was difficult to fuse visually on SBS PET/DCT (n = 1); a subcapsular liver metastasis not seen on CT and difficult to differentiate from a peritoneal deposit, metastatic lymph node, or physiologic uptake in the adjacent bowel on PET (n = 1); and a vertebral metastasis not seen on CT (n = 1). Two benign lesions had higher confidence scores for a benign lesion on PET/CT (lymph node [n = 1] and liver mass [n = 1]). An additional benign ovarian mass showed abnormal uptake of 18 F-FDG on PET. It was difficult to separate definitively from physiologic bowel uptake on SBS PET/DCT (n = 1). Although it received a ''higher'' confidence score for malignancy on fused PET/CT, it was false positive on both reading methods. On surgery, this turned out to be a benign cystadenoma of the ovary.
Comparison of CT Component of PET/CT With Diagnostic CT
Of the 27 discordant lesions analyzed, DCT and the CT component of PET/CT identified 11 lesions. Only 4 of these lesions (2.4% of all lesions assessed) were scored differently by the 2 readers: a small peritoneal nodule and a small lung mass not identified on a DCT scan, a presacral mass, and a small lymph node in a gastrohepatic ligament. The latter 2 lesions were thought to be benign on DCT but were suspected as being malignant on the CT portion of the PET/CT study. All these discordant lesions grew in size during the time interval between DCT and PET/CT (range: 4-6 weeks). Two liver lesions were identified only on a contrast-enhanced DCT scan. Because both were associated with increased 18 F-FDG uptake, they were correctly interpreted as malignant on SBS PET/DCT and fused PET/CT.
DISCUSSION
Positron emission tomography/CT is a new and evolving imaging modality. Several editorials have been published on the potential strengths of PET/CT compared with PET or CT when performed alone for oncologic assessment, especially when evaluating abdominal and pelvic malignancies. [7] [8] [9] Studies comparing PET/CT with SBS PET/DCT are still scarce, however. [10] [11] [12] Pelosi et al 10 published a study comparing the value of integrated PET/CT and separate PET plus morphologic imaging studies for lesion localization in cancer patients. These authors found that PET/CT had only 3.4% ambiguous shows a subcentimetric lymph node in presacral fat (arrow). Positron emission tomography (middle image) shows focal uptake (arrow); however, it cannot be definitively localized to the lymph node and was thought prospectively to represent physiologic uptake in the adjacent sigmoid colon. Fused PET/CT (right image) correctly localizes abnormal uptake of 18 F-FDG to the small lymph node (arrow), shown on surgery to be metastatic. lesions compared with 15.3% with PET and correlative imaging (P , 0.0001), with most of the lesions being located below the diaphragm (although the difference was not statistically significant). In that study, CT was used only for lesion localization and comparison was made in 2 different groups of patients. Recently, Reinartz et al 11 published a study comparing in-line PET/CT with SBS PET/DCT. The authors assessed lesion localization and infiltration of adjacent organs and found that SBS PET/DCT was not sufficient, compared with PET/CT, in 6% of lesions (6.7% of patients). These results are not unlike the results of the current study, with 9.5% of lesions found to be fundamentally discordant. Neither of the previous studies addressed the sensitivity and specificity of the reading methods or the potential use of the morphologic characteristics of the abnormalities provided by the CT part of PET/CT. A study recently published by Antoch et al 12 compared the tumor node metastasis staging of 260 patients with various oncologic diseases with CT alone, PET alone, SBS PET/CT, and integrated PET/CT. Positron emission tomography/CT was significantly more accurate when compared with all other modalities or reading methods assessed. This diagnostic advantage translated into treatment plan changes in 16 of 260 patients as compared with SBS reading of PET and CT. 12 This study, however, compared contrast-enhanced DCT studies performed with the same PET/CT system (and with the same field of view), which may overestimate the diagnostic performance of SBS PET and CT in that study.
The aim of the current study was to determine whether fused PET/CT indeed has a diagnostic advantage over SBS PET/DCT in the same patient population with PET and CT performed separately (as is the case in routine clinical practice), and if so, to determine in which types of lesions or body regions fused PET/CT might be beneficial. As would be intuitively expected, visual fusion of PET and CT may be suboptimal for small lesions, such as small lymph nodes (see Fig. 2 ), or lesions that may vary in position between examinations, such as peritoneal lesions (see Fig. 1 ) or lesions adjacent to loops of bowel. 13 As observed in our patient population, it may be difficult to localize small malignant deposits adjacent to the rib cage, small pleural deposits, or peritoneal deposits adjacent to solid organs (spleen or liver) correctly, especially when these are not clearly seen on CT. These focal regions of uptake may be mistaken for physiologic uptake in intercostal muscles, the diaphragm, or even skeletal muscles in the chest or abdominal wall. Abnormal uptake of 18 F-FDG in ovarian masses may be difficult to differentiate from physologic uptake of the bowel on visual fusion, as was the case in 2 of our patients. The more precise fusion of PET and CT with integrated PET/CT scanners offers a higher sensitivity in localizing such lesions (sensitivity of 100% for PET/CT vs. 38% for SBS PET/DCT).
The relative low specificity of fused PET/CT and SBS PET/DCT for discordant lesions can be attributed to inherent limitations of 18 F-FDG PET, because focal FDG uptake may be physiologic or seen in various benign abnormalities. For example, a false-positive ovarian mass on PET/CT (thought to represent physiologic bowel uptake on SBS PET/DCT) turned out to be a benign cystadenoma on surgical resection. In another case, a focal region of uptake in breast tissue with a soft tissue attenuating mass on CT was thought to represent malignancy on PET/CT. On SBS PET/DCT performed 1 month earlier, a subcutaneous port was seen in same location, indicating that the focal uptake likely represented a resolving hematoma after port removal (see Table 1 ). The 18 F-FDG uptake and soft tissue mass resolved on follow-up study despite no anticancer therapy in the interim.
The fact that DCT preceded the PET scan by several weeks was found to be a disadvantage in 4 patients. In 2 of the latter cases, lesions were not detectable, even in retrospect. In 2 additional cases, a significant change in the size of the lesion was seen despite a relatively short interval between the studies, making both lesions suspicious for malignancy on the CT portion of PET/CT but not on the DCT used for correlation.
Although the CT component of the PET/CT scan is performed with low mAs, using a free-breathing technique, and without administration of intravenous iodinated contrast in our routine protocol, we performed a separate blind reading of the CT component of the PET/CT scan and compared it with the DCT. This was done to determine if abnormalities not detected on DCT could be picked up on a more contemporary, albeit technically inferior, CT scan.
Although the latter CT scan could not identify all lesions identified on contrast-enhanced DCT when read alone, overlooking some of the lesions in parenchymal organs (liver and spleen), the PET/CT report correctly identified their presence because they were positive on the PET portion of the study.
A major limitation of the study is that the PET examinations, including PET alone, SBS PET/DCT, and PET/CT, were read by a single nuclear medicine physician. Thus, a potential recalling of results from the SBS PET/DCT method could have affected the PET/CT reading. We do not think that this limitation in study design affected the study results, however, because all but 1 of the discordant lesions were not better assessed on the SBS PET/DCT as compared with PET/CT. Conversely, differences caused by interobserver variability were avoided for the PET part of the study.
In conclusion, in-line PET/CT offers better lesion localization in comparison to visual fusion of PET and CT, especially for small lymph nodes, lesions adjacent to mobile organs, or lesions adjacent to the chest or abdominal wall. Diagnostic CT used for comparison performed within 6 weeks of the PET scan may be inadequate, even when compared with technically inferior lower dose CT, because of changes that may occur in this patient population even during a short time gap.
